Clinical trials: IPMN
IPMN, IPMN, Pancreatic
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
- Trial name
- NCT04207944
- Testing
- Sulindac 400 MG
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Duke University
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Diabetes, IPMN, Pancreatic
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g.
- Conditions
- Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- LASERBLOOD (NCT07659639)
- Testing
- Diagnostic procedures
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
IPMN, Pancreatic, Pancreatic Cancer, Resected
Venous Resection in Patients Undergoing Pancreatic Surgery
Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved.
- Conditions
- IPMN, Pancreatic, Pancreatic Cancer, Resected, Pancreatic Cancer Borderline, Chronic Pancreatitis
- Trial name
- VENUS (NCT07621029)
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 1,000 people
- Sponsor
- Sahlgrenska University Hospital
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer, Diagnose Disease
AI-Powered Precision Decision-Making for Pancreatic Diseases
This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases.
- Conditions
- Pancreatic Cancer, Diagnose Disease, IPMN, Pancreatic, Pancreatic Cystic Lesions
- Trial name
- NCT07439757
- Testing
- Diagnosis by Artificial Intelligence model
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Changhai Hospital
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Pancreas Head Cancer, Pancreas Adenocarcinoma
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of…
- Conditions
- Pancreas Head Cancer, Pancreas Adenocarcinoma, IPMN, Pancreatic, Cholangio Carcinoma
- Trial name
- PANENCA (NCT07262957)
- Testing
- HOP bundle
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IPMN, Pancreatic
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare.
- Trial name
- INCITE (NCT06694792)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS San Raffaele
Neoplasm of Pancreas, IPMN, Pancreatic
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous…
- Trial name
- NCT06519097
- Testing
- Vitamin E Delta Tocotrienol
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
IPMN, Pancreatic
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Intraductal papillary mucinous neoplasms (IPMN) are one of the main precursor lesions of pancreatic ductal adenocarcinoma (PDAC), a lethal disease predicted to become the second leading cause of cancer-related deaths in Western…
- Trial name
- NCT06574373
- Testing
- Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention
- Where
- 2 sites in Italy
- Volunteers
- 3,600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Pancreatic Cancer, IPMN, Pancreatic
Pancreatic Cancer Initial Detection Via Liquid Biopsy
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient…
- Conditions
- Pancreatic Cancer, IPMN, Pancreatic, Individuals at Risk, Chronic Pancreatitis
- Trial name
- PANCAID (NCT06283576)
- Testing
- Liquid biopsy
- Where
- Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
IPMN, Pancreatic, IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure.
- Trial name
- MAPS (NCT05117723)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- St Vincent's Hospital Melbourne
IPMN, Pancreatic
A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm
Study objective: To establish a long-term follow-up cohort of patients with IPMN, study the follow-up, clinical outcomes and prognostic factors of patients with IPMN, and provide a basis for clinical decisions and guidelines.
- Trial name
- NCT05593393
- Testing
- Endoscopic ultrasound
- Volunteers
- 1,500 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cyst, Pancreas Cyst
Feasibility of Molecular Biology in Pancreatic Cyst Tumors
The main objective of the study is to compare the diagnostic accuracy of intra-cystic fluid DNA molecular analysis to standard diagnostics.
- Conditions
- Pancreatic Cyst, Pancreas Cyst, Serous Cystadenoma, Mucinous Cystadenoma
- Trial name
- CYST-GEN (NCT03305146)
- Testing
- Molecular biology analysis of pancreatic intra-cyst fluid
- Where
- 11 sites in France
- Volunteers
- 93 people
- Sponsor
- Hospital St. Joseph, Marseille, France
Oral Microbiome, Pancreatic Cancer
Pancreatic Cancer and Oral Microbiome
Pancreatic cancer (PC) is a solid malignancy with a dismal prognosis. It has a 5-year survival rate of approximately 8%. This is due to the usually late diagnosis, to chemoresistance, and to intrinsic biological aggressiveness.
- Conditions
- Oral Microbiome, Pancreatic Cancer, IPMN, Parodontopathy
- Trial name
- NCT04993846
- Testing
- Dental plaque sampling, qPCR
- Where
- 2 sites in Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU
Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)
Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma with pejorative prognosis. IPMNs require characterization to clarify their potential for degeneration.
- Trial name
- IPMN (NCT04901364)
- Testing
- Sensitivity and specificity of risk factors for degeneration of IPMNs
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Central Hospital, Nancy, France
Pancreatic Cancer, Pancreatitis
TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Aim of the prospective study is a better differentiation of benign and malignant lesions in the pancreas in patients with suspected pancreatic cancer using images 30 and 90 min p.i.
- Conditions
- Pancreatic Cancer, Pancreatitis, IPMN
- Trial name
- TOF-P (NCT03914950)
- Testing
- PET/CT results with TOF/without TOF
- Volunteers
- 174 people
- Sponsor
- Medical University of Graz